Tags : Mitsubishi Tanabe

Mitsubishi Tanabe Signs a License Agreement with Viela Bio for

Shots: Veila Bio to receive $30M upfront licensing fee, additional payment on development and commercial milestones plus royalties on sales of product post-launch MTPC to get exclusive rights to develop and commercialize the product in Japan, South Korea, Taiwan, Singapore, Indonesia, Thailand, Malaysia, the Philippines and Vietnam   Inebilizumab is an anti-CD19 mAb that binds […]Read More

Mitsubishi Tanabe Reports Initiation of P-III BouNDLess Trial in Patients

Shots: The P-III BouNDLess study involves assessing of continuous carbidopa/levodopa (ND0612, SC) infusion vs immediate-release carbidopa/levodopa (CD/LD, PO) in 300 patients with PD experiencing motor fluctuations, evaluating its safety, efficacy and tolerability Mitsubishi’s subsidiary NeuroDerm is leading the P-III study with primary objective to determine the effect of ND0612 on daily “GOOD ON” time as […]Read More